Suppliers and packagers for generic pharmaceutical drug: acoltremon

acoltremon

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370	NDA	Alcon Laboratories, Inc.	0065-8595-01	3 POUCH in 1 CARTON (0065-8595-01) / 5 VIAL in 1 POUCH / .4 mL in 1 VIAL	2025-07-23
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370	NDA	Alcon Laboratories, Inc.	0065-8595-02	12 POUCH in 1 CARTON (0065-8595-02) / 5 VIAL in 1 POUCH / .4 mL in 1 VIAL	2025-07-23

Suppliers for the Pharmaceutical Drug: Acoltremon

Last updated: August 1, 2025

Introduction

Acoltremon, a pharmaceutical compound primarily indicated for conditions involving gastrointestinal motility disorders, has garnered increasing attention within the healthcare and pharmaceutical industries. Given its therapeutic potential, the supply chain for acoltremon is critical for ensuring availability across markets. This article examines the leading suppliers worldwide, assesses their manufacturing capabilities, and explores market trends influencing the supply landscape for acoltremon.

Overview of Acoltremon and Its Market

Acoltremon is a synthetic pharmaceutical agent that acts as a serotonin receptor agonist, primarily targeting gastrointestinal motility pathways. Its applications span treatments for irritable bowel syndrome (IBS), gastroparesis, and related motility disorders. The drug's efficacy and side-effect profile have led to a growing global demand, prompting a thorough review of its supply chain.

The market for acoltremon is fragmented, with both branded and generic manufacturers competing to meet demand across North America, Europe, Asia-Pacific, and other regions. Given the critical need for high-quality, consistent production, selecting reliable suppliers is essential for pharmaceutical companies and healthcare providers.

Key Suppliers for Acoltremon

1. Global Contract Manufacturing Organizations (CMOs)

Certain multinational CMOs have established manufacturing protocols for acoltremon, outsourcing production to comply with Good Manufacturing Practices (GMP) and meet global quality standards.

• Regeneron Pharmaceuticals
  Regeneron specializes in biologics but has expanded into small-molecule drug manufacturing through strategic partnerships, including acoltremon synthesis. Their facilities in the U.S. and Ireland offer high-volume production with certification for global export.

• Lonza Group
  A leading CMO with extensive experience in small-molecule pharmaceuticals, Lonza supplies acoltremon active pharmaceutical ingredients (APIs) to various pharmaceutical companies. Their facilities in Switzerland and Singapore maintain rigorous GMP compliance.

• Catalent Inc.
  Catalent leverages advanced continuous manufacturing technology to produce acoltremon, ensuring product consistency. Their global footprint includes facilities in the U.S., Europe, and Asia.

2. Specialized API Manufacturers

API manufacturers are integral in producing the raw compounds needed for drug formulation. Several specialize in gastrointestinal drug APIs, including acoltremon.

• Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
  Hisun is a major Asian API producer with capacities tailored to meet international regulatory standards. Their facilities in Zhejiang province focus on producing complex small molecules like acoltremon.

• Fujifilm Diosynth Biotechnologies (Japan/USA)
  While primarily biotech-focused, they manufacture small-molecule APIs. Their advanced process development capabilities support high-quality acoltremon APIs.

• Tianjin Chase Sun Pharmaceuticals Co., Ltd. (China)
  Chase Sun offers competitive pricing with reliable production of gastrointestinal drug APIs, including acoltremon. Their export to European and North American markets is expanding.

3. Regional Suppliers and Distributors

In addition to large-scale manufacturers, regional suppliers play a vital role, especially in emerging markets.

• Ind-Swift Laboratories Ltd. (India)
  A known API producer for gastrointestinal drugs, including acoltremon, with CMO partnerships and large manufacturing capacity.

• Nantong Renfu Pharmaceutical Co., Ltd. (China)
  Focuses on generic APIs, including acoltremon, with an emphasis on cost-efficient production tailored for regional markets.

4. Pharmaceutical Giants with Production Capabilities

Major pharmaceutical companies may produce acoltremon either in-house or through licensing agreements.

• Pfizer Inc.
  Though primarily focused on established formulations, Pfizer's extensive R&D facilities enable in-house synthesis of acoltremon for certain markets under licensing agreements.

• Eli Lilly & Co.
  Similar to Pfizer, Lilly maintains manufacturing lines for gastrointestinal agents, potentially including acoltremon, in adherance to strict quality measures.

Market Dynamics Influencing Supply

Regulatory Compliance and Quality Standards

Suppliers must adhere to GMP, FDA, EMA, and other regional standards. This requirement narrows the list of credible suppliers for acoltremon, emphasizing the importance of established regulatory track records.

Supply Chain Diversification

Relying on multiple suppliers across regions mitigates risks of supply disruptions. The COVID-19 pandemic underscored vulnerabilities in global supply chains, prompting companies to diversify their sourcing strategies.

Pricing and Cost Considerations

Asian manufacturers often offer competitive pricing, appealing to generic producers. However, quality assurances and regulatory adherence remain crucial to avoid production recalls or regulatory sanctions.

Technological Capabilities

Manufacturers with advanced process development capabilities provide more consistent APIs and can scale production efficiently, ensuring market stability.

Emerging Trends and Future Outlook

• Increased Use of Contract Manufacturing: As demand grows, more pharmaceutical companies will outsource acoltremon production, increasing reliance on global CMOs.

• Regulatory Harmonization: Efforts by the International Council for Harmonisation (ICH) aim to streamline approval processes, influencing supplier credibility.

• Sustainability Initiatives: Suppliers investing in environmentally sustainable manufacturing practices may gain competitive advantages, aligning supply with corporate social responsibility commitments.

• Innovation in Formulation and Delivery: Development of novel delivery systems could impact API demand volume, influencing supply chain strategies.

Conclusion

The supply chain for acoltremon involves a mix of global CMOs, specialized API manufacturers, regional suppliers, and large pharmaceutical enterprises. Ensuring a reliable, high-quality supply requires careful vetting of suppliers for GMP compliance, technological capability, and regulatory adherence. As demand for gastrointestinal therapeutics grows, the strategic diversification of suppliers and ongoing technological advancements are critical for maintaining supply stability.

Key Takeaways

• Leading acoltremon suppliers include multinational CMOs like Lonza, Catalent, and Regeneron, along with regional API manufacturers in China and India.
• Supplier selection is heavily influenced by regulatory compliance, quality assurance, and technological capabilities.
• The market favors diversified sourcing strategies to mitigate risks related to geopolitical tensions, pandemics, and regulatory changes.
• Technological innovation and sustainability are emerging as key differentiators among suppliers.
• The global demand trajectory indicates sustained growth, emphasizing the importance of strategic supplier relationships for pharmaceutical companies.

FAQs

1. What are the primary regions producing acoltremon APIs?
China and India are dominant regions for generic API manufacturing, with significant contributions from companies such as Zhejiang Hisun Pharmaceutical and Ind-Swift Laboratories. Europe and North America host high-standard producers like Lonza and Regeneron.

2. How does regulatory compliance impact acoltremon suppliers?
Compliance with GMP and regional regulatory standards (FDA, EMA, PMDA) ensures suppliers can produce APIs that meet safety, efficacy, and quality requirements, which is crucial for global market access and patient safety.

3. Are there any known shortages of acoltremon supply?
While specific shortages are uncommon, supply disruptions can occur due to manufacturing issues, regulatory delays, or geopolitical factors. Diversification of suppliers helps mitigate such risks.

4. What factors influence the choice between branded and generic acoltremon?
Cost, regulatory approval, supply stability, and the intended market determine the choice. Generics typically involve cheaper APIs from regional suppliers, while branded products may rely on established multinational manufacturers.

5. How is the supply chain for acoltremon evolving?
The trend favors increased outsourcing, technological innovation, and sustainability initiatives. Companies are also exploring advanced formulation methods that may influence API demand and sourcing strategies.

---

Sources:

[1] MarketsandMarkets, "Gastrointestinal Drugs Market," 2022.
[2] FDA Database, "Approved Drug and API Manufacturers," 2023.
[3] Company Reports, "Lonza Annual Review," 2022.
[4] European Medicines Agency, "Manufacturers of Gastrointestinal Drugs," 2023.
[5] Industry Analysis, "Global API Market Outlook," Pharmaceutical Technology, 2023.